Can-Fite BioPharma Ltd. (CANF)
| Market Cap | 29.73M |
| Revenue (ttm) | 580,571 |
| Net Income (ttm) | -2.74M |
| Shares Out | 2.69M |
| EPS (ttm) | -1.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $1.90 |
| Previous Close | $1.90 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 1.92 |
| Day's Range | 1.88 - 1.92 |
| Day's Volume | 34,101 |
| 52-Week Range | 1.13 - 2.76 |
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers
Petach Tikva, Israel--(Newsfile Corp. - January 4, 2021) - Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs th...
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address ...
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Reports on Progress with its Namodenoson NASH Program
Can-Fite BioPharma Ltd. (CANF) CEO Pnina Fishman on Q3 2020 Results - Earnings Call Transcript
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite's Namodenoson Abstract Selected as ‘Best of The Liver Meeting ‘ in the NASH Category of the American Association of Liver Diseases (AASLD)
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of AASLD Conference
With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 ...
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address ...
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Selected to Deliver Late-Breaking Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Participate in Two BioPharma Partnering Conferences
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020
PETACH TIKVA, Israel--(BUSINESS WIRE)--FDA Clears Can-Fite to Commence Phase II COVID-19 Study
Can-Fite BioPharma Ltd. (CANF) CEO Pnina Fishman on Q2 2020 Results - Earnings Call Transcript
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address ...
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Conduct Investor Call to Review Q2 Results and Provide Business Update on Thursday, August 27, 2020 at 4:15 p.m. ET
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly
Can-Fite BioPharma Ltd. (CANF) CEO Pnina Fishman on Q1 2020 Results - Earnings Call Transcript
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 27th
As the COVID-19 pandemic continues to ravage the globe, having claimed over 115,000 lives, health care companies have are pursuing diagnostics tests, potential vaccines and therapies.
Can-Fite BioPharma (NYSE: CANF) shares were trading higher on Tuesday, after the company announced it achieved its main study endpoint in phase 2 NASH study with Namodenoson were dose-dependent.
The following are the latest biotech announcements from late Thursday and Friday morning on the development of products targeting the coronavirus.
Can-Fite (CANF) announces plans to explore piclidenoson for the treatment of coronavirus.
PETACH TIKVA, Israel, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule ...
Can-Fite BioPharma Ltd CANF 3.77% , an Israeli biotechnology company with a pipeline of proprietary compounds in Phase 2 and 3 clinical development stage that address autoimmune-inflammator...
Israeli biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) said Monday that its drug candidate Piclidenoson for the treatment of osteoarthritis in mammals has been granted Patent No.
Biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) announced Tuesday it has partnered with the medical cannabis company Univo Pharmaceuticals to work on developing cannabinoid-based ph...
Shares of Can-Fite Biopharma Ltd. CANF, -2.05% soared 18% in active premarket trading Tuesday, after the Israel-based drug development company announced a collaboration agreement with Israeli ...
Can-Fite BioPharma (NYSE: CANF) announced a new deal with Kyongbo Pharm to distribute the drug Piclidenoson for Psoriasis in South Korea, receiving $4 million payment upfront.
Can-Fite BioPharma (NYSE: CANF) 6-K shows the company filed an appeal with the Supreme Court of Israel of a decision related to the convening of a special shareholder meeting to replace direct...
Can-Fite (CANF) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
In Q1/2019, Can-Fite reported that Namodenoson didn’t achieve the primary endpoint in the Phase 2 liver cancer study, but achieved superiority in median overall survival in a subgroup.
Shares of the biotech Can-Fite Biopharma Ltd were skyrocketing Monday after an abstract describing data from the company's liver cancer study of the drug namodenoson was selected by the Intern...
About CANF
Can-Fite BioPharma, a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis;... [Read more...]
| Industry Biotechnology | Founded 1994 |
| CEO Pnina Fishman | Employees 8 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol CANF |
Financial Performance
In 2019, CANF's revenue was 2.03 million, a decrease of -46.81% compared to the previous year's 3.82 million. Losses were -9.59 million, 45.9% more than in 2018.
Analyst Forecasts
According to one analyst, the rating for CANF stock is "Buy" and the 12-month stock price forecast is 5.00.